Table S7. Associations of clinical characteristics and survival within the sensitivity analyses. (DOC 146 kb
List of LUNG SAFE investigators. Names and affiliations of the LUNG SAFE investigators. (PDF 172Â kb
Table S8. Patientsâ characteristics and clinical endpoints of immunocompromised (study) patients, ...
Online supplement (DOC). Figure S1. Histograms showing propensity score distribution. Table S1. Base...
Table S6. Proportion of treated comorbid conditions according to sensitivity analyses. (DOC 60 kb
Table S5. Prescription patterns of comorbidity-relevant medication according to sensitivity analyses...
Table S4. Baseline characteristics of the study sample within Sensitivity Analysis 2. (DOC 56 kb
Figure S2. Comorbidity prevalence in main analysis compared with sensitivity analyses. (DOC 104 kb
Table S2. Prescription patterns of comorbidity-relevant medication at the subtype level. (DOC 75 kb
Table S3. ILD subtype-specific hazard ratios as per the comorbidity-only Cox model. (DOC 97 kb
Figure S3. Pneumoconios-, Drug-associated ILD-, Radiation-asscociated pneumonitis-, Eosinophilic pne...
Treatment modality in treatment group (nâ=â86). Table S2. Comorbidities of study population. Tab...
Table S1. A summary of the primary etiologies included in non-IPF ILD group. Table S2. Individual-le...
Table S5. Factors associated with hospital mortality in immunocompromised patients. Multivariate log...
Table S1. Ten-Year CVD Risk by GOLD classification and selected baseline characteristics in COPD pat...
Comorbidities among respiratory diseases. Figure S1. Comorbidities* between respiratory diseases and...
List of LUNG SAFE investigators. Names and affiliations of the LUNG SAFE investigators. (PDF 172Â kb
Table S8. Patientsâ characteristics and clinical endpoints of immunocompromised (study) patients, ...
Online supplement (DOC). Figure S1. Histograms showing propensity score distribution. Table S1. Base...
Table S6. Proportion of treated comorbid conditions according to sensitivity analyses. (DOC 60 kb
Table S5. Prescription patterns of comorbidity-relevant medication according to sensitivity analyses...
Table S4. Baseline characteristics of the study sample within Sensitivity Analysis 2. (DOC 56 kb
Figure S2. Comorbidity prevalence in main analysis compared with sensitivity analyses. (DOC 104 kb
Table S2. Prescription patterns of comorbidity-relevant medication at the subtype level. (DOC 75 kb
Table S3. ILD subtype-specific hazard ratios as per the comorbidity-only Cox model. (DOC 97 kb
Figure S3. Pneumoconios-, Drug-associated ILD-, Radiation-asscociated pneumonitis-, Eosinophilic pne...
Treatment modality in treatment group (nâ=â86). Table S2. Comorbidities of study population. Tab...
Table S1. A summary of the primary etiologies included in non-IPF ILD group. Table S2. Individual-le...
Table S5. Factors associated with hospital mortality in immunocompromised patients. Multivariate log...
Table S1. Ten-Year CVD Risk by GOLD classification and selected baseline characteristics in COPD pat...
Comorbidities among respiratory diseases. Figure S1. Comorbidities* between respiratory diseases and...
List of LUNG SAFE investigators. Names and affiliations of the LUNG SAFE investigators. (PDF 172Â kb
Table S8. Patientsâ characteristics and clinical endpoints of immunocompromised (study) patients, ...
Online supplement (DOC). Figure S1. Histograms showing propensity score distribution. Table S1. Base...
DOI
Add to ORKG